160 related articles for article (PubMed ID: 38178900)
1. RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer.
Behrens A; Wurmthaler L; Heindl F; Gass P; Häberle L; Volz B; Hack CC; Emons J; Erber R; Hartmann A; Beckmann MW; Ruebner M; Dougall WC; Press MF; Fasching PA; Huebner H
Geburtshilfe Frauenheilkd; 2024 Jan; 84(1):77-85. PubMed ID: 38178900
[TBL] [Abstract][Full Text] [Related]
2. Correlation of RANK and RANKL with mammographic density in primary breast cancer patients.
Wunderle M; Heindl F; Behrens AS; Häberle L; Hack CC; Heusinger K; Huebner H; Gass P; Ruebner M; Schulz-Wendtland R; Erber R; Hartmann A; Beckmann MW; Dougall WC; Press MF; Fasching PA; Emons J
Arch Gynecol Obstet; 2024 Jun; ():. PubMed ID: 38836929
[TBL] [Abstract][Full Text] [Related]
3. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.
Reyes ME; Fujii T; Branstetter D; Krishnamurthy S; Masuda H; Wang X; Reuben JM; Woodward WA; Edwards BJ; Hortobagyi GN; Tripathy D; Dougall WC; Eckhardt BL; Ueno NT
Breast Cancer Res Treat; 2017 Jul; 164(1):57-67. PubMed ID: 28417335
[TBL] [Abstract][Full Text] [Related]
4. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
[TBL] [Abstract][Full Text] [Related]
5. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
6. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
7. RANK expression as a prognostic and predictive marker in breast cancer.
Pfitzner BM; Branstetter D; Loibl S; Denkert C; Lederer B; Schmitt WD; Dombrowski F; Werner M; Rüdiger T; Dougall WC; von Minckwitz G
Breast Cancer Res Treat; 2014 Jun; 145(2):307-15. PubMed ID: 24737168
[TBL] [Abstract][Full Text] [Related]
8. The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.
Zhang L; Teng Y; Fan Y; Wang Y; Li W; Shi J; Ma Y; Li C; Shi X; Qu X; Liu Y
Oncotarget; 2015 Sep; 6(26):22918-33. PubMed ID: 26087197
[TBL] [Abstract][Full Text] [Related]
9. Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis.
Zhang X; Song Y; Song N; Zhang L; Wang Y; Li D; Wang Z; Qu X; Liu Y
Braz J Med Biol Res; 2018 Jan; 51(3):e6265. PubMed ID: 29340518
[TBL] [Abstract][Full Text] [Related]
10. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
11. RANK and RANKL Expression in Salivary Gland Tumors.
Aslan F; Küçük Ü
Ear Nose Throat J; 2020 Aug; 99(7):475-480. PubMed ID: 32525717
[TBL] [Abstract][Full Text] [Related]
12. RANK and RANK ligand expression in primary human osteosarcoma.
Branstetter D; Rohrbach K; Huang LY; Soriano R; Tometsko M; Blake M; Jacob AP; Dougall WC
J Bone Oncol; 2015 Sep; 4(3):59-68. PubMed ID: 27556008
[TBL] [Abstract][Full Text] [Related]
13. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.
Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
J Exp Clin Cancer Res; 2013 Sep; 32(1):62. PubMed ID: 24011086
[TBL] [Abstract][Full Text] [Related]
14. Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma.
Steven A; Leisz S; Fussek S; Nowroozizadeh B; Huang J; Branstetter D; Dougall WC; Burchardt M; Belldegrun AS; Seliger B; Pantuck A; Kroeger N
Urol Oncol; 2018 Nov; 36(11):502.e15-502.e24. PubMed ID: 30170981
[TBL] [Abstract][Full Text] [Related]
15. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
[TBL] [Abstract][Full Text] [Related]
16. The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?
Li R; Zhang K; Penedo TL; Kragel CP; Grizzle WE; Hameed O; Siegal GP; Wei S
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):42-50. PubMed ID: 26200837
[TBL] [Abstract][Full Text] [Related]
17. Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis.
Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Yang X; Liu Y; Qu X
J Clin Pathol; 2012 Jan; 65(1):36-40. PubMed ID: 22049226
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients.
Santini D; Schiavon G; Vincenzi B; Gaeta L; Pantano F; Russo A; Ortega C; Porta C; Galluzzo S; Armento G; La Verde N; Caroti C; Treilleux I; Ruggiero A; Perrone G; Addeo R; Clezardin P; Muda AO; Tonini G
PLoS One; 2011 Apr; 6(4):e19234. PubMed ID: 21559440
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
20. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
